Strongbridge Biopharma plc Announces Publication of Diabetes Subgroup Analysis from Phase 3 ...
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Strongbridge Biopharma plc Announces Publication of Diabetes Subgroup Analysis from Phase 3 ... Strongbridge Biopharma plcApril 7, 2021 GMT RECORLEV® (levoketoconazole) Treatment Demonstrates Clinically Meaningful Improvements in Cortisol Control and Clinical Benefit in Patients with Cushing’s Syndrome and Comorbid Diabetes Mellitus DUBLIN, Ireland and TREVOSE, Pa., April 07, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company f...
Source: apnews.com